Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cingulate Inc (CING)
NASDAQ:CING
Cingulate Inc (CING) Stock Price & Analysis
117 Followers
CING Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.28 - $16.74
Previous Close$0.4
Volume915.23K
Average Volume (3M)496.33K
Market Cap
$3.05M
Enterprise Value$4.67M
Total Cash (Recent Filing)$1.99M
Total Debt (Recent Filing)$3.60M
Price to Earnings (P/E)―
Beta-0.92
Next Earnings
Aug 12, 2024EPS Estimate
-$0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-23.91
Shares Outstanding6,046,479
10 Day Avg. Volume155,931
30 Day Avg. Volume496,329
Standard Deviation0.32
R-Squared0.03
Alpha-0.08
Financial Highlights & Ratios
Price to Book (P/B)-36.38
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.23
Forecast
1Y Price Target
$20.00Price Target Upside5732.60% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Cingulate Inc News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe company reported positive Topline results that demonstrated a positive effect in subjects that received CTx-1301 versus subjects that received placebo.
New Business WinsIveda Solutions, Inc. is gaining traction with new business wins and increasing demand for its smart city, enterprise, and government solutions.
ValuationThe current valuation is very attractive, representing significant upside from the current share price and appropriately balancing out high risks with large upside opportunities.
Bears Say
Capital RequirementsCingulate finished 1Q24 with $1.1M in cash and requires capital needs of $9M-$10M to support operations for the remainder of 2024.
Clinical TrialsCingulate paused clinical trials for CTx-1301 for treating ADHD due to financial constraints.
Financial PerformanceThe company reported a net loss of $3.0 million or EPS of $(0.60).
---
Ownership Overview
34.79% Insiders
0.13% Mutual Funds
1.34% Other Institutional Investors
63.74% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
CING FAQ
What was Cingulate Inc’s price range in the past 12 months?
Cingulate Inc lowest stock price was $0.28 and its highest was $16.74 in the past 12 months.
What is Cingulate Inc’s market cap?
Currently, no data Available
When is Cingulate Inc’s upcoming earnings report date?
Cingulate Inc’s upcoming earnings report date is Aug 12, 2024 which is in 26 days.
How were Cingulate Inc’s earnings last quarter?
Currently, no data Available
Is Cingulate Inc overvalued?
According to Wall Street analysts Cingulate Inc’s price is currently Undervalued.
Does Cingulate Inc pay dividends?
Cingulate Inc does not currently pay dividends.
What is Cingulate Inc’s EPS estimate?
Cingulate Inc’s EPS estimate is -$0.47.
How many shares outstanding does Cingulate Inc have?
Cingulate Inc has 7,641,643 shares outstanding.
What happened to Cingulate Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Cingulate Inc?
Among the largest hedge funds holding Cingulate Inc’s share is GoalVest Advisory LLC. It holds Cingulate Inc’s shares valued at 1K.
---
Cingulate Inc Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.00 (5732.60% Upside)
$20.00 (5732.60% Upside)
Hedge Fund Trend
Increased
By 1.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 1.4%
Last 30 Days ▼ 1.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-97.47%
12-Months-Change
Fundamentals
Return on Equity
-1364.73%
Trailing 12-Months
Asset Growth
-23.29%
Trailing 12-Months
Company Description
Cingulate Inc
Cingulate Inc is a clinical stage biopharmaceutical company utilizing its proprietary precision timed release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes.
---
CING Stock 12 Month Forecast
Average Price Target
$20.00
▲(5732.60% Upside)
Technical Analysis
Best Analysts Covering CING
1 Year
1 Year Success Rate
0/5 ratings generated profit
1 Year Average Return
-79.48%
reiterated a buy rating 2 months ago
Copying Edward Woo's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -79.48% per trade.
---